190 related articles for article (PubMed ID: 34763666)
21. Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer.
Roa-Peña L; Leiton CV; Babu S; Pan CH; Vanner EA; Akalin A; Bandovic J; Moffitt RA; Shroyer KR; Escobar-Hoyos LF
Sci Rep; 2019 Aug; 9(1):11239. PubMed ID: 31375762
[TBL] [Abstract][Full Text] [Related]
22. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
Parker BA; Shatsky RA; Schwab RB; Wallace AM; ; Wolf DM; Hirst GL; Brown-Swigart L; Esserman LJ; van 't Veer LJ; Ghia EM; Yau C; Kipps TJ
Breast Cancer Res Treat; 2023 Jun; 199(2):281-291. PubMed ID: 37029329
[TBL] [Abstract][Full Text] [Related]
23. Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis.
Geng M; Cao YC; Chen YJ; Jiang H; Bi LQ; Liu XH
World J Gastroenterol; 2012 Mar; 18(12):1328-38. PubMed ID: 22493546
[TBL] [Abstract][Full Text] [Related]
24. WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma.
Arensman MD; Kovochich AN; Kulikauskas RM; Lay AR; Yang PT; Li X; Donahue T; Major MB; Moon RT; Chien AJ; Dawson DW
Oncogene; 2014 Feb; 33(7):899-908. PubMed ID: 23416978
[TBL] [Abstract][Full Text] [Related]
25. ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma.
Zheng YZ; Ma R; Zhou JK; Guo CL; Wang YS; Li ZG; Liu LX; Peng Y
Sci Rep; 2016 Nov; 6():36447. PubMed ID: 27830754
[TBL] [Abstract][Full Text] [Related]
26. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis.
Gao HL; Liu L; Qi ZH; Xu HX; Wang WQ; Wu CT; Zhang SR; Xu JZ; Ni QX; Yu XJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):95-100. PubMed ID: 29576277
[TBL] [Abstract][Full Text] [Related]
27. ROR1 and ROR2-novel targets for neuroblastoma.
Dave H; Butcher D; Anver M; Bollard CM
Pediatr Hematol Oncol; 2019 Sep; 36(6):352-364. PubMed ID: 31441359
[No Abstract] [Full Text] [Related]
28. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
[TBL] [Abstract][Full Text] [Related]
29. Expression of Wnt5a and ROR2, Components of the Noncanonical Wnt-Signaling Pathway, is Associated with Tumor Differentiation in Hepatocellular Carcinoma.
Wakizaka K; Kamiyama T; Kakisaka T; Orimo T; Nagatsu A; Aiyama T; Shichi S; Taketomi A
Ann Surg Oncol; 2024 Jan; 31(1):262-271. PubMed ID: 37814183
[TBL] [Abstract][Full Text] [Related]
30. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
31. Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance?
Gebauer F; Kemper M; Sauter G; Prehm P; Schumacher U
PLoS One; 2017; 12(6):e0178703. PubMed ID: 28582436
[TBL] [Abstract][Full Text] [Related]
32. Wnt-11 Expression Promotes Invasiveness and Correlates with Survival in Human Pancreatic Ductal Adeno Carcinoma.
Dart DA; Arisan DE; Owen S; Hao C; Jiang WG; Uysal-Onganer P
Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31718047
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of hepatocyte growth factor activator inhibitor type 1 (HAI-1) immunoreactivity in pancreatic ductal adenocarcinoma.
Sakugawa C; Haruyama Y; Tanaka H; Fukushima T; Kawaguchi M; Kataoka H
BMC Res Notes; 2017 Dec; 10(1):674. PubMed ID: 29202869
[TBL] [Abstract][Full Text] [Related]
34. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.
Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N
Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147
[TBL] [Abstract][Full Text] [Related]
35. Cellular and molecular mechanisms implicated in the dual role of ROR2 in cancer.
Castro MV; Lopez-Bergami P
Crit Rev Oncol Hematol; 2022 Feb; 170():103595. PubMed ID: 35032666
[TBL] [Abstract][Full Text] [Related]
36. GOT1/AST1 expression status as a prognostic biomarker in pancreatic ductal adenocarcinoma.
Feld FM; Nagel PD; Weissinger SE; Welke C; Stenzinger A; Möller P; Lennerz JK
Oncotarget; 2015 Feb; 6(6):4516-26. PubMed ID: 25595905
[TBL] [Abstract][Full Text] [Related]
37. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
38. ROR1 expression as a biomarker for predicting prognosis in patients with colorectal cancer.
Zhou JK; Zheng YZ; Liu XS; Gou Q; Ma R; Guo CL; Croce CM; Liu L; Peng Y
Oncotarget; 2017 May; 8(20):32864-32872. PubMed ID: 28427197
[TBL] [Abstract][Full Text] [Related]
39. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
[TBL] [Abstract][Full Text] [Related]
40. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma.
Liu QH; Shi ML; Bai J; Zheng JN
Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
